Nureca Ltd
Incorporated in 2016, Nureca Ltd is in the business of home healthcare and wellness products[1]
- Market Cap ₹ 274 Cr.
- Current Price ₹ 274
- High / Low ₹ 469 / 240
- Stock P/E
- Book Value ₹ 194
- Dividend Yield 0.00 %
- ROCE -4.02 %
- ROE -3.14 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 8.23% over past five years.
- Company has a low return on equity of 4.81% over last 3 years.
- Promoter holding has decreased over last 3 years: -6.23%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: E-Commerce/App based Aggregator Industry: Trading
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
61.90 | 99.43 | 213.45 | 255.55 | 111.32 | 91.93 | 90.80 | |
52.85 | 89.74 | 151.91 | 200.05 | 126.33 | 102.13 | 104.19 | |
Operating Profit | 9.05 | 9.69 | 61.54 | 55.50 | -15.01 | -10.20 | -13.39 |
OPM % | 14.62% | 9.75% | 28.83% | 21.72% | -13.48% | -11.10% | -14.75% |
0.09 | 0.06 | 2.82 | 7.70 | 7.11 | 10.51 | 13.60 | |
Interest | 0.24 | 0.77 | 1.60 | 0.74 | 0.45 | 0.49 | 0.71 |
Depreciation | 0.06 | 0.37 | 0.42 | 1.48 | 2.39 | 2.36 | 2.47 |
Profit before tax | 8.84 | 8.61 | 62.34 | 60.98 | -10.74 | -2.54 | -2.97 |
Tax % | 29.52% | 25.78% | 25.60% | 26.27% | -23.18% | -29.53% | |
6.23 | 6.40 | 46.37 | 44.96 | -8.25 | -1.79 | -2.80 | |
EPS in Rs | 6,230.00 | 6,400.00 | 46.37 | 44.96 | -8.25 | -1.79 | -2.80 |
Dividend Payout % | 0.00% | 0.00% | 4.31% | 6.67% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | -24% |
TTM: | -11% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -395% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -43% |
1 Year: | -23% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 5% |
Last Year: | -3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.01 | 0.01 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Reserves | 7.94 | 14.92 | 153.10 | 193.20 | 184.88 | 183.11 | 184.31 |
0.43 | 9.78 | 3.89 | 4.41 | 3.33 | 2.52 | 5.31 | |
15.14 | 9.17 | 18.76 | 11.52 | 8.38 | 9.53 | 15.34 | |
Total Liabilities | 23.52 | 33.88 | 185.75 | 219.13 | 206.59 | 205.16 | 214.96 |
0.54 | 1.06 | 3.68 | 10.19 | 8.65 | 7.11 | 9.35 | |
CWIP | 0.00 | 0.00 | 0.30 | 0.42 | 0.00 | 0.27 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 33.19 | 59.09 | 93.63 | 4.27 |
22.98 | 32.82 | 181.77 | 175.33 | 138.85 | 104.15 | 201.34 | |
Total Assets | 23.52 | 33.88 | 185.75 | 219.13 | 206.59 | 205.16 | 214.96 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
0.31 | -7.92 | 34.87 | 1.40 | 10.23 | -2.71 | |
-0.12 | -0.39 | -110.04 | -3.09 | -16.47 | 17.57 | |
-0.14 | 8.28 | 92.34 | -7.30 | -1.51 | -1.30 | |
Net Cash Flow | 0.04 | -0.04 | 17.17 | -8.99 | -7.75 | 13.56 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 52.24 | 47.35 | 0.38 | 4.13 | 14.10 | 6.43 |
Inventory Days | 123.18 | 92.82 | 134.95 | 173.89 | 166.63 | 185.75 |
Days Payable | 88.73 | 32.94 | 32.07 | 12.99 | 24.11 | 31.13 |
Cash Conversion Cycle | 86.70 | 107.24 | 103.26 | 165.02 | 156.61 | 161.05 |
Working Capital Days | 44.70 | 85.39 | 61.75 | 110.76 | 160.43 | 179.07 |
ROCE % | 56.69% | 66.71% | 32.61% | -6.27% | -4.02% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Directorate
2d - Appointment of Dr. Rupinder Tewari and Dr. Kuldip Kumar Bhasin as directors.
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
16 Nov - Nureca enters distribution agreement with Zepto.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
25 Oct - Newspaper publication - Financial Results for the second quarter and half year ended September 30, 2024
- Announcement under Regulation 30 (LODR)-Investor Presentation 24 Oct
- Financial Results For The Quarter And Half Year Ended September 30, 2024 24 Oct
Business Overview:[1][2]
NL is a D2C healthcare and wellness company with a USFDA, CE, FSSAI, and ISO 13485-certified product range of over 150 SKUs across different categories. It supports diagnosis, treatment, and prevention of illness through monitoring & analysis of health data.